Hunter Perkins Capital Management LLC Sells 729 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Hunter Perkins Capital Management LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 10,887 shares of the biopharmaceutical company’s stock after selling 729 shares during the period. Regeneron Pharmaceuticals accounts for approximately 1.9% of Hunter Perkins Capital Management LLC’s portfolio, making the stock its 13th largest position. Hunter Perkins Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $8,403,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its position in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at $226,000. Global Retirement Partners LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at $310,000. CreativeOne Wealth LLC boosted its position in Regeneron Pharmaceuticals by 49.2% during the second quarter. CreativeOne Wealth LLC now owns 776 shares of the biopharmaceutical company’s stock valued at $407,000 after acquiring an additional 256 shares during the last quarter. Finally, J.W. Cole Advisors Inc. boosted its position in Regeneron Pharmaceuticals by 3.5% during the second quarter. J.W. Cole Advisors Inc. now owns 997 shares of the biopharmaceutical company’s stock valued at $523,000 after acquiring an additional 34 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 2.5%

REGN opened at $737.71 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company has a market cap of $77.99 billion, a P/E ratio of 17.75, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41. The company has a fifty day moving average price of $764.67 and a two-hundred day moving average price of $707.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $12.07 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were paid a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,274 shares of company stock worth $4,142,738 in the last three months. Insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several research analyst reports. Evercore lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Barclays started coverage on Regeneron Pharmaceuticals in a report on Friday, March 6th. They issued an “overweight” rating and a $923.00 target price for the company. Finally, Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research note on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.